IDXX — IDEXX Laboratories, Inc.

Is IDXX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Oversold As of August 19, 2026

IDEXX Laboratories, Inc. (IDXX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $562.20. The rating moved from Strong Oversold to Oversold on August 19, 2026.

See all oversold Healthcare stocks →

AI analysis

IDEXX benefits from a durable, recurring-revenue business centered on veterinary diagnostics, instruments, and reference lab services with healthy margins and cash flow. Its installed base and proprietary tests create strong customer retention and pricing flexibility, while product innovation and digital/AI-enabled diagnostic adoption present medium-term upside. Key near-term sensitivities include a high valuation, consumer-spending trends that affect veterinary visit volumes, competitive pressures in diagnostics, and potential supply or regulatory headwinds. With quiet macro headlines in the latest window, corporate fundamentals and upcoming earnings commentary are likely to determine short-term price action.

Key factors

  • Leading market position in veterinary diagnostics and consumables with a high recurring-revenue base from point-of-care tests, reagents, and subscription services
  • Strong gross margins and cash generation driven by proprietary test franchises and installed diagnostic instrument base
  • Exposure to favorable diagnostic/screening thematic tailwinds (AI-enabled diagnostics and higher procedural volumes) that support long-term lab services growth
  • Diverse revenue streams (in-clinic instruments, reference lab services, software/telemedicine partnerships) that reduce single-channel dependence
  • Proven history of innovation and product commercialization, supporting pricing power and customer stickiness
  • Limited near-term macro headline risk in the provided market window, allowing fundamentals and earnings commentary to drive flows

Risks

  • Premium valuation could amplify downside in a broad risk-off move or if growth slows versus elevated expectations
  • Demand for veterinary services and elective procedures is somewhat consumer-discretionary and can be sensitive to household spending and inflation
  • Competition from other diagnostics firms and potential new entrants into point-of-care and lab services could pressure share or pricing
  • Supply-chain disruptions or manufacturing capacity constraints for instruments/reagents could delay revenue recognition
  • Regulatory changes affecting diagnostics, lab operations, or cross-border service delivery could increase compliance costs
  • FX exposure and acquisition/integration risk for any material M&A that alters capital allocation or margin profile

See today's live rating, score and targets

Members see the live hourly rating for IDXX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.